The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity

Archiv der Pharmazie

Volumn 341, Issue 7, 2008, Pages 405-411

  Hagmann, William K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bioactivation; Cannabinoid receptor; Inverse agonist; Obesity; Taranabant

Indexed keywords

CANNABINOID 1 RECEPTOR AGONIST; RIMONABANT; TARANABANT; AMIDE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; N (3 (4 CHLOROPHENYL) 2 (3 CYANOPHENYL) 1 METHYLPROPYL) 2 METHYL 2 ((5 (TRIFLUOROMETHYL)PYRIDIN 2 YL)OXY)PROPANAMIDE; N-(3-(4-CHLOROPHENYL)-2-(3-CYANOPHENYL)-1-METHYLPROPYL)-2-METHYL-2-((5-(TRIFLUOROMETHYL)PYRIDIN-2-YL)OXY)PROPANAMIDE; PYRIDINE DERIVATIVE;

AREA UNDER THE CURVE; DRUG ACTIVITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFECT; DRUG SCREENING; INVERSE AGONISM; RAT;

AMIDES; ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INVERSE AGONISM; HUMANS; OBESITY; PYRIDINES; RATS; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 52449108446     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200700255     Document Type: Review

References (27)

1. G. A. Bray, J. Med. Chem. 2006, 49, 4001-4007.
2. W. Trojniar, R. A. Wise, Psychopharmacol. 1991, 103, 172-176.
3. J. Antel, P. C. Gregory, U. Nordheim, J. Med. Chem. 2006, 49, 4008-4016;
4. F. Barth in Annual Reports in Medicinal Chemistry (Ed.: A. M. Doherty), Academic Press, NY, 2005; Vol. 40, pp. 103-118;
5. R. Pertwee, AAPS J. 2005, 7, E625-E654;
6. G. G. Muccioli, D. M. Lambert, Curr. Med. Chem. 2005, 12, 1361-1394;
7. B. Le Foll, S. R. Goldberg, J. Pharmacol. Exp. Ther. 2005, 312, 875-883.
8. E. V. Gelfand, C. P. Cannon, J. Am. Coll. Cardiol. 2006, 47, 1919-1926;
9. L. F. Van Gaal, A. M. Rissanen, A. J. Scheen, O. Ziegler, S. Rossner, RIO - Europe Study Group, Lancet 2005, 365, 1389-1397.
10. C. W. Plummer, P. E. Finke, S. G. Mills, J. Wang, et al., Bioorg. Med. Chem. Lett. 2005, 15, 1441-1446.
11. L. P. Shearman, D. S. Stribling, R. E. Camacho, K. M. Rosko, et al., Eur. J. Pharmacol. 2008, 579, 215-224.
12. L. C. Meurer, P. E. Finke, S. G. Mills, T. F. Walsh, et al., Bioorg. Med. Chem. Lett. 2005, 15, 645-651.
13. J. S. Debenham, C. B. Madsen-Duggan, T. F. Walsh, J. Wang, et al., Bioorg. Med. Chem. Lett. 2006, 16, 681-685.
14. E. M. Schultz, W. A. Bolhofer, J. K. Horner, S. F. Kwong, A. M. Pietruszkiewcz, J. Med. Chem. 1967, 10, 717-724.
15. L. S. Lin, T. J. Lanza, J. P. Jewell, P. Liu, et al., J. Med. Chem. 2006, 49, 7584-7587.
16. H. S. Pines, J. M. Chemerda, M. A. Kozlowski, G. W. Lindberg, J. Med. Chem. 1967, 10, 725-728.
17. H. E. Armstrong, A. Galka, L. S. Lin, T. J. Lanza, et al., Bioorg. Med. Chem. Lett. 2007, 17, 2184-2187.
18. J. Uetrecht, Ann. Rev. Pharmacol. Toxicol. 2007, 47, 513-539.
19. D. C. Evans, A. P. Watt, D. A. Nicoll-Griffith, T. A. Baillie, Chem. Res. Toxicol. 2004, 17, 3-16.
20. C. E. C. A. Hop, A. S. Kalgutkar, J. R. Soglia in Annual Reports in Medicinal Chemistry (Ed.: A. Wood), Academic Press, NY, 2006; Vol. 41, pp. 369-381.
21. K. Samuel, W. Yin, R. A. Stearns, Y. S. Tang, et al., J. Mass Spectrom. 2003, 38, 211-221.
22. T. M. Fong, X.-M. Guan, D. J. Marsh, C.-P. Shen, et al., J. Pharmacol. Exp. Ther. 2007, 321, 1013-1022.
23. C. Addy, H. Wright, K. V. Laere, I. Gantz, et al., Cell Metab. 2008, 7, 1-11.
24. R. Frank, R. Hargreaves, Nat. Rev. 2003, 2, 566-582.
25. N. S. Mason, C. A. Mathis in Annual Reports in Medicinal Chemistry (Ed.: A. Wood), Academic Press, NY, 2005; Vol. 40, pp. 49-68.
26. P. Liu, L. S. Lin, T. G. Hamill, J. P. Jewell, et al., J. Med. Chem. 2007, 50, 3427-3430.
27. H. D. Burns, K. Van Laere, S. Sanbria-Bohoquez, T. G. Hamill, et al., Proc. Nat. Acad. Sci. USA 2007, 104, 9800-9805.